Progyny, Inc. (NASDAQ:PGNY) Receives $34.36 Consensus PT from Brokerages

Progyny, Inc. (NASDAQ:PGNY) has been assigned an average rating of “Moderate Buy” from the thirteen research firms that are currently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $34.3636.

Several analysts have recently issued reports on the stock. Weiss Ratings cut shares of Progyny from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Barclays dropped their price target on Progyny from $34.00 to $30.00 and set an “equal weight” rating for the company in a research report on Wednesday, August 12th. Citigroup reissued an “outperform” rating on shares of Progyny in a research note on Tuesday, September 8th. Citizens Jmp upped their price objective on Progyny from $31.00 to $33.00 and gave the company a “market outperform” rating in a research report on Tuesday, September 8th. Finally, Wall Street Zen raised Progyny from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 19th.

Insiders Place Their Bets

In other Progyny news, Director Kevin Gordon sold 11,500 shares of the firm’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $27.94, for a total value of $321,310.00. Following the completion of the sale, the director owned 6,792 shares of the company’s stock, valued at $189,768.48. This trade represents a 62.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 9.90% of the company’s stock.

Hedge Funds Weigh In On Progyny

Institutional investors have recently made changes to their positions in the company. Hsbc Holdings PLC acquired a new position in shares of Progyny in the second quarter valued at about $760,000. Easterly Investment Partners LLC lifted its holdings in shares of Progyny by 197.4% during the fourth quarter. Easterly Investment Partners LLC now owns 146,013 shares of the company’s stock worth $3,750,000 after purchasing an additional 96,912 shares during the period. AWM Investment Company Inc. acquired a new stake in shares of Progyny during the second quarter worth about $6,343,000. Bank of America Corp DE boosted its position in Progyny by 75.3% in the first quarter. Bank of America Corp DE now owns 1,190,996 shares of the company’s stock valued at $20,223,000 after buying an additional 511,609 shares during the last quarter. Finally, Royal Bank of Canada boosted its position in Progyny by 98.0% in the first quarter. Royal Bank of Canada now owns 218,434 shares of the company’s stock valued at $3,709,000 after buying an additional 108,137 shares during the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Progyny Stock Performance

Shares of PGNY stock opened at $25.83 on Monday. Progyny has a 52-week low of $16.10 and a 52-week high of $33.06. The firm has a market capitalization of $1.98 billion, a PE ratio of 28.08, a PEG ratio of 1.81 and a beta of 0.99. The stock has a fifty day simple moving average of $28.01 and a two-hundred day simple moving average of $24.48.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.33 by $0.22. Progyny had a return on equity of 15.98% and a net margin of 6.00%.The business had revenue of $350.51 million for the quarter, compared to the consensus estimate of $349.05 million. During the same period in the previous year, the business earned $0.19 earnings per share. The business’s revenue was up 5.3% on a year-over-year basis. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, sell-side analysts forecast that Progyny will post 1.25 EPS for the current fiscal year.

Progyny Company Profile

Progyny, Inc is a benefits management company that provides fertility and family-building solutions to employers and their employees. Its platform is designed to support individuals and couples pursuing fertility treatment, including in vitro fertilization, egg freezing, donor services, gestational surrogacy and adoption.

The company’s services combine access to a network of fertility specialists with personalized guidance, care coordination and treatment support. Progyny also offers pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States.